Recent 8-K filings for LIMN

• August 18, 2026, 4:06 PM ET other material materiality 0.75 negative item 3.01item 3.03item 5.03item 7.01item 9.01

  Liminatus Pharma announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

  Board approved 1-for-50 reverse stock split; effective at close of trading Aug 20, 2026; split-adjusted trading on Nasdaq Capital Market Aug 21, 2026 under LIMN.

• July 29, 2026, 9:49 PM ET regulatory materiality 0.60 neutral item 8.01item 9.01

  Liminatus Pharma believes it meets Nasdaq equity minimum after InnocsAI merger

  Company believes stockholders' equity now exceeds $2.5 million following merger with InnocsAI LLC.

• July 24, 2026, 4:51 PM ET regulatory materiality 0.75 negative item 3.01item 8.01item 9.01

  Liminatus Pharma receives Nasdaq notice of non-compliance with Bid Price Rule; Panel to decide on continued listing

  Received Nasdaq notice on July 20, 2026 that it has not regained compliance with $1 minimum bid price rule and is not eligible for second 180-day extension.

• July 6, 2026, 9:13 AM ET M&A materiality 0.85 neutral item 1.01item 2.01item 3.02item 5.03item 9.01

  Liminatus Pharma closes merger with InnocsAI; issues 11.2M common shares and 158.9K Series A preferred

  Merger closed July 2, 2026; Liminatus acquired InnocsAI, a CAR-T therapy company.

• June 3, 2026, 5:14 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 3.03item 8.01item 9.01 ◈ Equity Issuances◈ Material Agreements

  Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares

  Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.

• May 27, 2026, 4:30 PM ET other material materiality 0.85 negative item 3.01item 9.01 ◈ Listing & Compliance Notices

  Liminatus Pharma receives Nasdaq delisting notice; appeals filed

  On May 20, 2026, Nasdaq notified Liminatus Pharma it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.

• May 20, 2026, 5:00 PM ET M&A materiality 0.75 neutral item 1.01item 9.01 ◈ Material Agreements

  Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M

  1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.

• February 9, 2026, 6:59 PM ET litigation materiality 0.70 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances◈ Material Agreements

  Liminatus Pharma issues 4M shares to settle $7.5M default judgment, dismisses lawsuits

  Issued 4,000,000 shares to Clear Street LLC in exchange for surrender of 805,377 warrants.

• January 26, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01item 9.01 ◈ Listing & Compliance Notices

  Liminatus Pharma receives Nasdaq bid price deficiency notice; 180 days to regain compliance

  Received Nasdaq deficiency notice on Jan 15, 2026 for failing to maintain $1 minimum bid price for 30 consecutive business days.

• November 25, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01item 9.01 ◈ Listing & Compliance Notices

  Liminatus Pharma receives Nasdaq delisting notices for failing MVLS and MVPHS rules

  Notices dated Nov 19, 2025: MVLS below $50M and MVPHS below $15M for 30 consecutive business days.

• July 17, 2025, 7:59 PM ET other material materiality 0.65 positive item 1.01item 3.02item 9.01

  Liminatus Pharma exchanges 1M warrants for 350K shares with Alta Partners

  Company issued 350,000 shares of common stock to Alta Partners in exchange for surrender and cancellation of 1,000,000 warrants.

• July 3, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity

  Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.

• June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025

  IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.

• June 2, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 2.01item 9.01item 1.01item 5.02item 3.02item 4.01

  Liminatus Pharma completes de-SPAC business combination, files Q1 2025 financials

  Business combination closed April 30, 2025; combined company trades on Nasdaq as LIMN and LIMNW.

• May 6, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 5.02item 3.02item 4.01item 9.01item 3.03item 5.01item 5.03item 5.05item 5.06item 7.01item 8.01 ◈ Governance Changes ×3◈ M&A Transactions

  Liminatus Pharma completes de-SPAC merger, receives $15M PIPE, begins Nasdaq trading

  Closed de-SPAC merger with Iris Acquisition Corp; issued 17.5M shares at $10/share ($175M equity value) to Liminatus securityholders.

• April 30, 2025, 7:59 PM ET M&A materiality 0.80 positive item 9.01

  Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN

  Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

6 positive 6 negative 12 neutral

source · LIMN on sec.gov